18/08/2025
Could Natural Killer (NK) cell-derived extracellular vesicles (EVs) revolutionise how we fight cancer?
While NK cells are powerful cancer killers, direct cell therapy faces hurdles such as poor tumour infiltration, short survival times and immunogenicity. NK-EVs: are nano-sized vesicles (30-150 nm) that carry a cancer-fighting arsenal derived from their parent cells but with some distinct advantages:
✅ Enhanced tumour pe*******on due to small size
✅ Non-immunogenic and inherently safe and scalable manufacture
✅ Can be engineered to carry additional therapeutic cargo
Recent NK-EV studies show promising anti-tumour activity across breast, colon, ovarian, and brain cancers. IL-15-treated NK-EVs demonstrated enhanced cytotoxic effects against glioblastoma and other aggressive cancers.
This positions NK-EVs as potentially transformative for solid tumours, traditionally challenging for immunotherapy. While challenges remain in large-scale production and standardisation, the potential to combine NK-EVs with existing immunotherapies such as checkpoint inhibitors opens fascinating possibilities.
Read the article https://lnkd.in/eNdDNEXC